Online inquiry

IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11840MR)

This product GTTS-WQ11840MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11840MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7469MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ4218MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ4374MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ5603MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ13974MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ1344MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-806
GTTS-WQ11847MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ11897MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MLN-1202
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW